Lantern Pharma Inc. (LTRN) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 2 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-1.92 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1,930.92 vs est $-1.92 (missed -100731.3%). 2025: actual $-1.57 vs est $-1.67 (beat +6%). Analyst accuracy: 47%.
LTRN Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to Lantern Pharma Inc. in the past 3 months
EPS Estimates — LTRN
47%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1,930.92
vs Est –$1.92
▼ 99.9% off
2025
Actual –$1.57
vs Est –$1.67
▲ 6.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — LTRN
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
